Authors: Reddy, KR Wright, TL Pockros, PJ Shiffman, M Everson, G Reindollar, R Fried, MW Purdum, PP Jensen, D Smith, C Lee, WM Boyer, TD Lin, A Pedder, S DePamphilis, J

Citation: Kr. Reddy et al., Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared withinterferon alpha-2a in noncirrhotic patients with chronic hepatitis C, HEPATOLOGY, 33(2), 2001, pp. 433-438

Authors: Kimball, P Elswick, RK Shiffman, M

Citation: P. Kimball et al., Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy, J MED VIROL, 65(3), 2001, pp. 510-516

Authors: Manns, MP McHutchinson, JG Gordon, SC Rustgi, VK Shiffman, M Reindollar, R Goodman, ZD Koury, K Ling, MH Albrecht, JK

Citation: Mp. Manns et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plusribavirin for initial treatment of chronic hepatitis C: a randomised trial, LANCET, 358(9286), 2001, pp. 958-965

Authors: Fried, MW Shiffman, M Sterling, RK Weinstein, J Crippin, J Garcia, G Wright, TL Conjeevaram, H Reddy, KR Peter, J Cotsonis, GA Nolte, FS

Citation: Mw. Fried et al., A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: Pretreatment stratification by viral burden and genotype, AM J GASTRO, 95(11), 2000, pp. 3225-3229

Authors: Zeuzem, S Hopf, U Carreno, V Diago, M Shiffman, M Grune, S Dudley, FJ Rakhit, A Rittweger, K Yap, SH Koff, RS Thomas, HC

Citation: S. Zeuzem et al., A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C, HEPATOLOGY, 29(4), 1999, pp. 1280-1287